PHARMACOKINETICS AND SAFETY OF ELAFIBRANOR IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION

被引：0
|
作者：
Noel, Benoit [1 ]
Vargas, Dawn [2 ]
Georges-Coty, Anne [1 ]
Roudot, Alice [1 ]
Roux, Olivier [3 ]
Magrez, David [1 ]
Wyatt, David [4 ]
Birman, Pascal [1 ]
Addy, Carol [1 ,5 ]
机构：
[1] Genfit SA, Loos, France
[2] Genfit CORP, Loos, France
[3] It&m Stats, Neuilly Sur Seine, France
[4] Syneos Hlth, Morrisville, NC USA
[5] Genfit SA, Clin Dev, Loos, France
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1287
引用
收藏
页码：772A / 773A
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment
    Mao, Lily
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E402 - E402
  • [42] Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function
    Cawello, W
    Braun, M
    Horstmann, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1091 - 1091
  • [43] Ragaglitazar: Pharmacokinetics and safety in subjects with or without hepatic impairment
    Lundholm, H
    Pabst, G
    Skrumsager, BK
    Horak, J
    DIABETES, 2002, 51 : A489 - A489
  • [44] The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
    Aweeka, F
    Jayesekara, D
    Horton, M
    Swan, S
    Lambrecht, L
    Wilner, KD
    Sherwood, J
    Anziano, RJ
    Smolarek, TA
    Turncliff, RZ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 27S - 33S
  • [45] SAFETY AND PHARMACOKINETICS (PK) OF THE PROGESTERONE RECEPTOR MODULATOR VILAPRISAN IN SUBJECTS WITH IMPAIRED LIVER FUNCTION.
    Riecke, K.
    Chattopadhyay, N.
    Ligges, S.
    Zimmermann, T.
    Kohnke, A.
    Halabi, A.
    Schultze-Mosgau, M.
    FERTILITY AND STERILITY, 2018, 110 (04) : E135 - E135
  • [46] Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
    Custodio, Joseph M.
    Rhee, Martin
    Shen, Gong
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) : 2564 - 2569
  • [47] Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function
    Gordi, Toufigh
    Blackburn, Brent
    Lieu, Hsiao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (07): : 825 - 833
  • [48] Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-1a in Subjects with Normal or Impaired Renal Function
    Hu, Xiao
    Seddighzadeh, Ali
    Stecher, Scott
    Zhu, Ying
    Goyal, Jaya
    Matson, Mark
    Marbury, Thomas
    Smith, William
    Nestorov, Ivan
    Hung, Serena
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (02): : 179 - 188
  • [49] Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function
    Phillips, Marc
    Smith, William
    Balan, Guhan
    Ward, Suzanne
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (03): : 279 - 284
  • [50] Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function
    Nagy, CF
    Kumar, D
    Cullen, EI
    Bolton, WK
    Marbury, TC
    Gutierrez, MJ
    Hutman, HW
    Pratt, RD
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 : 18 - 24
12345